Underrepresentation of Women in Revascularization Trials

Celina M. Yong,William F. Fearon
DOI: https://doi.org/10.1001/jamacardio.2024.0768
2024-06-13
JAMA Cardiology
Abstract:One could argue that the most shocking finding across decades of large clinical trials that deeply investigate coronary revascularization is that women are still poorly represented in them. Cardiovascular disease (CVD) is the number 1 cause of death among both men and women in the US, yet decades of cardiovascular clinical trials have persistently enrolled a predominantly male population. Among all types of cardiovascular trials, coronary revascularization trials rank at the bottom in terms of representation by sex, with an average of 27% females enrolled across 141 coronary artery disease and 61 acute coronary syndrome trials from 2010 to 2017. 1 Despite recent concerted efforts to improve equity of trial enrollment, revascularization trials face ongoing challenges that deserve specific attention.
cardiac & cardiovascular systems
What problem does this paper attempt to address?